Author/Authors :
Payandeh, Mehrdad kermanshah university of medical sciences - Medical Biology Research Center, ايران , Shaveisi Zadeh, Farhad shahid beheshti university of medical sciences - Faculty of Medicine - Department of Medical Genetics, تهران, ايران , Zare, Mohammad Erfan kermanshah university of medical sciences - Medical Biology Research Center, ايران , Zare, Mohammad Erfan kermanshah university of medical sciences, ايران , Mansouri, Kamran kermanshah university of medical sciences - Medical Biology Research Center, ايران , Mansouri, Kamran tehran university of medical sciences tums - School of advanced Medical Technologies - Department of Molecular Medicine, تهران, ايران , Khodarahmi, Reza kermanshah university of medical sciences - Medical Biology Research Center, ايران , Khodarahmi, Reza kermanshah university of medical sciences - School of Medicine - Department of Biochemistry, ايران , Alimoradi, Saeed kermanshah university of medical sciences - Paramedical Faculty, ايران , Yousefi, Hoshang Research Center of Iranian Blood Transfusion Organization, ايران , Darabi, Fatemeh kermanshah university of medical sciences - Paramedical Faculty, ايران
Abstract :
Introduction: The myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterized by excessive production of blood cells by hematopoietic precursors. Typically, they include polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myelofibrosis (IMF), and chronic myeloid leukemia (CML). Philadelphia chromosome is the final diagnostic test for CML. Recently, JAK2 mutation introduced as a diagnostic marker for other MPNs. The aim of this study is evaluation of Philadelphia chromosome in CML patients and JAK2 mutation in MPNs patients that had been referred to a hematology/oncology clinic in Kermanshah between 2010-2011.Material and methods: In this study we evaluated common genetic disorders in 124 MPNs patients. Expression of B2A2 BCR-ABL mRNA in peripheral blood leucocytes was detected by a reverse transcriptase polymerase chain reaction (RT-PCR) for CML patients. Also, we used AS-RT-PCR method for the detection of the JAK2 mutation for all of 124 patients. Results: We found 93.7% CML patients (60/64) with positive Philadelphia chromosome. Also, 85% PV patients (17/20), 46.6% ET patients (14/30) and 40% IMF patients (4/10) had JAK2 mutation. Notably, we found a CML patient with positive Philadelphia chromosome and JAK2 mutation.Conclusion: Diagnosis of MPNs is often complex and expensive but, JAK2 mutation is a sensitive test, relatively cost-effective for proving clonality in MPNs. Also, more studies are required to determine the exact frequency and prognostic role of the JAK2 mutation in Philadelphia positive CML patients
